MedTrace Logo

TERPS Trial for de Novo Oligometastic Prostate Cancer

NCT05223803 · Status: RECRUITING · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 122

Last updated 2025-11-10

No results posted yet for this study

Summary

This research is being done to see if we can improve the outcome of prostate cancer patients who present with metastatic lesions at initial diagnosis.

Conditions

Interventions

RADIATION

Prostate radiation (XRT)

Both arms will receive prostate radiation. Multiple treatment regimens are allowed per protocol.

DRUG

Systemic Therapy

All systemic therapy is provided as best prescribed for patient per their medical oncologist.

RADIATION

Stereotactic ablative radiation therapy (SABR)

SABR is delivered to those randomized to Arm 2.

Sponsors & Collaborators

  • University of Maryland, Baltimore

    lead OTHER

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-10-18
Primary Completion
2026-07-31
Completion
2027-07-31
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05223803 on ClinicalTrials.gov